MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

MDT

82.89

+1.38%↑

VEEV

212.71

+0.2%↑

A

102.2

+2.21%↑

WBA

10.96

+1.29%↑

CHE

576

+1.7%↑

Search

Beam Therapeutics Inc

Open

SectorHealthcare

19.01 2.48

Overview

Share price change

24h

Current

Min

17.81

Max

19.03

Key metrics

By Trading Economics

Income

6.3M

-90M

Sales

16M

30M

EPS

-1.09

Profit margin

-300.509

Employees

483

EBITDA

16M

-85M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+166.65% upside

Dividends

By Dow Jones

Next Earnings

6 May 2025

Market Stats

By TradingEconomics

Market Cap

-852M

1.7B

Previous open

16.53

Previous close

19.01

News Sentiment

By Acuity

50%

50%

169 / 385 Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bullish Evidence

Beam Therapeutics Inc Chart

Past performance is not a reliable indicator of future results.

Related News

26 Sept 2024, 14:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Tanked A $5.4 Billion Takeover. Why Crispr, Agios, Beam Could Benefit. -- IBD

Peer Comparison

Price change

Beam Therapeutics Inc Forecast

Price Target

By TipRanks

166.65% upside

12 Months Forecast

Average 45.33 USD  166.65%

High 80 USD

Low 20 USD

Based on 15 Wall Street analysts offering 12 month price targets forBeam Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

12

Buy

3

Hold

0

Sell

Technical Score

By Trading Central

17.04 / N/ASupport & Resistance

Short Term

Very Strong Bullish Evidence

Intermediate Term

Very Strong Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

169 / 385 Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.